Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
27 10 2023
Historique:
medline: 30 10 2023
pubmed: 26 10 2023
entrez: 26 10 2023
Statut: ppublish

Résumé

Enteroendocrine cells (EECs) are hormone-producing cells residing in the epithelium of stomach, small intestine (SI), and colon. EECs regulate aspects of metabolic activity, including insulin levels, satiety, gastrointestinal secretion, and motility. The generation of different EEC lineages is not completely understood. In this work, we report a CRISPR knockout screen of the entire repertoire of transcription factors (TFs) in adult human SI organoids to identify dominant TFs controlling EEC differentiation. We discovered ZNF800 as a master repressor for endocrine lineage commitment, which particularly restricts enterochromaffin cell differentiation by directly controlling an endocrine TF network centered on PAX4. Thus, organoid models allow unbiased functional CRISPR screens for genes that program cell fate.

Identifiants

pubmed: 37883554
doi: 10.1126/science.adi2246
doi:

Substances chimiques

Repressor Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

451-458

Auteurs

Lin Lin (L)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Jeff DeMartino (J)

Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Daisong Wang (D)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Gijs J F van Son (GJF)

Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Reinier van der Linden (R)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Harry Begthel (H)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Jeroen Korving (J)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Amanda Andersson-Rolf (A)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Stieneke van den Brink (S)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Carmen Lopez-Iglesias (C)

The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Maastricht, Netherlands.

Willine J van de Wetering (WJ)

The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Maastricht, Netherlands.

Aleksandra Balwierz (A)

Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Thanasis Margaritis (T)

Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Marc van de Wetering (M)

Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Peter J Peters (PJ)

The Maastricht Multimodal Molecular Imaging Institute, Maastricht University, Maastricht, Netherlands.

Jarno Drost (J)

Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Johan H van Es (JH)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.

Hans Clevers (H)

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, Netherlands.
Oncode Institute, Utrecht, Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH